Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,325,276 papers from all fields of science
Search
Sign In
Create Free Account
SB 207499
Known as:
SB-207499
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Cilomilast
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
In vitro PKA phosphorylation‐mediated human PDE4A4 activation
F. Laliberté,
,
Susana Liu
,
+5 authors
Zheng Huang
FEBS Letters
2002
Corpus ID: 27637592
2002
2002
Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model
I. Schade
,
S. Roth-Eichhorn
,
+4 authors
S. Schüler
Transplantation
2002
Corpus ID: 7933649
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors…
Expand
2000
2000
PDE inhibitors--Second William Harvey Research Conference. Drugs with an expanding range of therapeutic uses. 1-3 December 1999, Nice, France.
T. Torphy
IDrugs : the investigational drugs journal
2000
Corpus ID: 30380859
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One…
Expand
1999
1999
Ariflo (SmithKline Beecham plc).
W. Brown
IDrugs : the investigational drugs journal
1999
Corpus ID: 41061044
Ariflo (SB-207499) is a phosphodiesterase (PDE)4 inhibitor under development by SmithKline Beecham and in phase III and II…
Expand
1997
1997
Phosphodiesterase inhibitors: the next generation
W. Elwood
1997
Corpus ID: 72112417
Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept…
Expand
1995
1995
Novel PDE IV inhibitors: exploring their potential in asthma
D. Jack
1995
Corpus ID: 72873994
&The enzyme phosphodiesterase (PDE) IV is a target for several companies seeking to develop innovative agents with both anti…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE